KALRAY
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge, is pleased to announce its vision for the present and future of high-performance computing at SC22 in Dallas, November 14-17, 2022. Hosting a number of solutions presentations for Dell Technologies Unstructured Data Solutions and HPC customers, alongside networking opportunities for attendees, Kalray will demonstrate how their highly complementary hardware and software solutions are addressing developments in the world of intensive data storage and processing.
Kalray solutions for both Unstructured Data Solutions and HPC storage provide enterprise customers with a comprehensive solution for compute, storage and data management. Kalray will be presenting its solutions this year in the Dell Technologies booth theater #2443.
“This is a great opportunity for Kalray to demonstrate its unique portfolio offerings for the HPC and Unstructured Data Solutions market.,” says Kalray CEO, Éric Baissus. “The presentations and activities at SC22 is part of our strategy to accelerate our go-to-market and strengthen our key position in the storage market.”
Specifically, with pixstor™ and ngenea®, Kalray now offers an all-in-one, easy-to-use solution that meets the requirements of most storage workloads. pixstor's™ "Tier Zero" scratch storage enables customers to dramatically increase storage performance, while ngenea® vastly improves efficiency by consolidating storage environments such as Dell PowerScale and ECS and simplifying data management workflows.
At SC22 attendees can join our presentations in the Dell Technologies booth theater #2443, where they will hear insights from Greg Furmidge, VP of Global Sales Operations, Kalray and Isaiah Weiner, Technical Solutions Architect, Kalray. They will be discussing offers for HPC and Unstructured Data Solutions enterprise customers featuring pixstor™, the high-performance storage software and ngenea®, the data-orchestration software.
PRESENTATION DETAILS
-
15th November 2022 at 11.00
Kalray pixstor™, Beyond Storage
Greg Furmidge, VP of Global Sales Operations, Kalray
-
15th November 2022 at 14:40
Accelerating Data-Driven HPC
Isaiah Weiner, Technical Solutions Architect, Kalray
Anthony Dina, Global Field CTO, Dell Technologies
-
16th November 2022 at 10:20
Kalray ngenea®, Beyond Cloud for Your Business Capabilities and Workflows
Isaiah Weiner, Technical Solutions Architect, Kalray
-
16th November 2022 at 14:40
Accelerating Data-Driven HPC
Isaiah Weiner, Technical Solutions Architect, Kalray
Anthony Dina, Global Field CTO, Dell Technologies
SPECIAL LEADERSHIP NETWORKING EVENT
In addition, Kalray and Dell are hosting a Cocktail and Networking event for industry leaders. Register via the link below to socialize, share and learn from technology leaders in a welcoming atmosphere.
- Date: Thursday 15th November at 17.00-19:00 in the Hard Shake Lounge. Register here.
For more information about the joint Kalray and Dell Technologies solutions, please check out our brief here:
- 5 Top Reasons why customer choose Dell PowerScale and Kalray solutions for on-demand data management
- Sales Solution brief for Dell PowerScale and Kalray pixstor™: a modern solution for high-performance computing
- Sales Solution brief for Dell PowerScale, ECS and Kalray ngenea®: a modern solution for data management
About KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
